TY - JOUR
T1 - Exercising the hepatobiliary-gut axis. The impact of physical activity performance
AU - Molina-Molina, Emilio
AU - Lunardi Baccetto, Raquel
AU - Wang, David Q.H.
AU - de Bari, Ornella
AU - Krawczyk, Marcin
AU - Portincasa, Piero
N1 - Publisher Copyright:
© 2018 Stichting European Society for Clinical Investigation Journal Foundation
PY - 2018/8
Y1 - 2018/8
N2 - Background: Physical inactivity puts the populations at risk of several health problems, while regular physical activity brings beneficial effects on cardiovascular disease, mortality and other health outcomes, including obesity, glycaemic control and insulin resistance. The hepatobiliary tract is greatly involved in several metabolic aspects which include digestion and absorption of nutrients in concert with intestinal motility, bile acid secretion and flow across the enterohepatic circulation and intestinal microbiota. Several metabolic abnormalities, including nonalcoholic fatty liver as well as cholesterol cholelithiasis, represent two conditions explained by changes of the aforementioned pathways. Materials and Methods: This review defines different training modalities and discusses the effects of physical activity in two metabolic disorders, that is nonalcoholic fatty liver disease (NAFLD) and cholelithiasis. Emphasis is given to pathogenic mechanisms involving intestinal bile acids, microbiota and inflammatory status. Results: A full definition of physical activity includes the knowledge of aerobic and endurance exercise, metabolic equivalent tasks, duration, frequency and intensity, beneficial and harmful effects. Physical activity influences the hepatobiliary-gut axis at different levels and brings benefits to fat distribution, liver fat and gallbladder disease while interacting with bile acids as signalling molecules, intestinal microbiota and inflammatory changes in the body. Conclusions: Several beneficial effects of physical activity are anticipated on metabolic disorders linking liver steatosis, gallstone disease, gut motility, enterohepatic circulation of signalling bile acids in relation to intestinal microbiota and inflammatory changes.
AB - Background: Physical inactivity puts the populations at risk of several health problems, while regular physical activity brings beneficial effects on cardiovascular disease, mortality and other health outcomes, including obesity, glycaemic control and insulin resistance. The hepatobiliary tract is greatly involved in several metabolic aspects which include digestion and absorption of nutrients in concert with intestinal motility, bile acid secretion and flow across the enterohepatic circulation and intestinal microbiota. Several metabolic abnormalities, including nonalcoholic fatty liver as well as cholesterol cholelithiasis, represent two conditions explained by changes of the aforementioned pathways. Materials and Methods: This review defines different training modalities and discusses the effects of physical activity in two metabolic disorders, that is nonalcoholic fatty liver disease (NAFLD) and cholelithiasis. Emphasis is given to pathogenic mechanisms involving intestinal bile acids, microbiota and inflammatory status. Results: A full definition of physical activity includes the knowledge of aerobic and endurance exercise, metabolic equivalent tasks, duration, frequency and intensity, beneficial and harmful effects. Physical activity influences the hepatobiliary-gut axis at different levels and brings benefits to fat distribution, liver fat and gallbladder disease while interacting with bile acids as signalling molecules, intestinal microbiota and inflammatory changes in the body. Conclusions: Several beneficial effects of physical activity are anticipated on metabolic disorders linking liver steatosis, gallstone disease, gut motility, enterohepatic circulation of signalling bile acids in relation to intestinal microbiota and inflammatory changes.
KW - G protein–coupled bile acid receptor-1
KW - bile acids
KW - farnesoid X receptor
KW - gallstone disease
KW - gut microbiota
KW - nonalcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85050571083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050571083&partnerID=8YFLogxK
U2 - 10.1111/eci.12958
DO - 10.1111/eci.12958
M3 - Review article
C2 - 29797516
AN - SCOPUS:85050571083
SN - 0014-2972
VL - 48
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 8
M1 - e12958
ER -